News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Drug interactions and pharmacokinetics news

Show

From To
New and experimental HIV treatments
Cobicistat matches ritonavir as atazanavir booster

The new boosting agent cobicistat works as well as ritonavir (Norvir) as a pharmaco-enhancer or booster for the first-line protease inhibitor atazanavir (Reyataz) at 48 weeks, according to

Published
30 July 2012
By
Liz Highleyman
TB treatment
Tuberculosis: Combined wisdom

Buried in the HIV frenzy at the International AIDS Conference was a rather important announcement for another blight, tuberculosis.

Published
26 July 2012
From
The Economist
HIV treatment in children
Efavirenz Works in Kids with Both HIV and TB

Children co-infected with HIV and tuberculosis appear to suppress both infections when treated with standard TB regimens and an efavirenz-based HIV regimen, researchers said here at the International AIDS Conference.

Published
25 July 2012
From
MedPage Today HIV/AIDS
New and experimental HIV treatments
Similar Efficacy, Side Effects in Study of Gilead Booster Cobicistat and Norvir

Compared with Norvir (ritonavir), people living with HIV using Gilead Sciences’ novel boosting agent cobicistat were just as likely to see their viral loads drop to undetectable levels and no more likely to discontinue therapy due to side effects, according to preliminary results from a Phase III study comparing both drugs in combination with Reyataz (atazanavir) and Truvada (tenofovir plus emtricitabine).

Published
25 July 2012
From
AIDSMeds
TB treatment
Co-administration of rifampicin and efavirenz does not reduce efavirenz concentrations or efficacy

Standard dosing of efavirenz, that was not adjusted for patient weight, resulted in therapeutic efavirenz concentrations and excellent virological outcomes in patients coinfected with TB and HIV

Published
24 July 2012
By
Lesley Odendal
TB treatment
UCSF/SFGH Researchers Call for Change in New FDA Recommendation on HIV and TB Drug Doses

In January, 2012, the U.S. Food and Drug Administration (FDA) issued new guidelines on dosing of an HIV medication used to treat people infected with both HIV and tuberculosis (TB). Now, a new analysis by the University of California, San Francisco (UCSF) and the San Francisco General Hospital and Trauma Center (SFGH) suggests this recommended dose adjustment may not be necessary, particularly in non-Caucasian populations.

Published
24 July 2012
From
USCF News Center
Hepatitis C treatment
No evidence of an interaction between abacavir and ribavirin

There is no evidence of an interaction between the anti-HIV drug abacavir and the anti-hepatitis C agent ribavirin, investigators report in the online edition of AIDS. Some earlier

Published
17 July 2012
By
Michael Carter
Infectiousness and treatment as prevention
Study shows that use of darunavir/ritonavir and etravirine in HIV treatment as a prevention method is biologically plausible

A pharmacokinetic study suggests that ritonavir-boosted darunavir (Prezista) and etravirine (Intelence) achieve high concentrations in semen and rectal tissue, and could therefore help avert HIV transmission and infection, especially

Published
13 June 2012
By
Michael Carter
New and experimental HIV treatments
Gilead Files European Marketing Application for Boosting Agent Cobicistat

Gilead Sciences, Inc. announced today that the Marketing Authorisation Application (MAA) for cobicistat, submitted on April 26, 2012, has been validated by the European Medicines Agency (EMA).

Published
25 May 2012
From
Gilead press release
Drug interactions and pharmacokinetics
13th International workshop on Clinical Pharmacology of HIV Therapy 16–18 April 2012, Barcelona

This important annual workshop always includes studies that are not presented to other meetings.

Published
23 May 2012
From
i-base
← Prev12345...14Next →

Filter by country